Insulet, headquartered in Acton, Massachusetts, develops and markets insulin infusion systems, including the Omnipod 5 Automated Insulin Delivery System, for insulin-dependent diabetes. The company employs 3,000 staff and went public in 2007.
Insulet (PODD) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Insulet's actual EPS was $1.17, beating the estimate of $0.95 per share, resulting in a 23.70% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
